FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Virchow: The Largest Foundation Model for Computational Pathology To Date August 13, 2024 A Clinical Signal of Efficacy Observed with a Combination of Nivolumab... June 20, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab July 8, 2021 Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 Load more HOT NEWS Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... Our COVID-19 Response: How We’re Supporting Frontline Workers At Revolution Foods AI and remote monitoring are shaping a new patient journey in... November is National Family Caregivers Month
